PROBING EBV-LMP-1'S TRANSMEMBRANE ACTIVATION DOMAIN WITH SYNTHETIC PEPTIDE ANTAG

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 尽管有许多治疗策略可以从外部接近分子靶点， 细胞内（例如治疗性抗体）或细胞质内（例如小分子 抑制剂），它们不适用于位于膜双层内的分子靶标。 疏水磷脂双层对水溶性极性物质施加了一个不可穿透的屏障， 治疗剂。我们正在探测EBV-LMP-1的跨膜激活结构域， 合成肽拮抗剂，试图找到新的LMP-1复合物。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Although many therapeutic strategies exist for molecular targets accessible from the outside of the cell (e.g. therapeutic antibodies) or within the cytoplasm (e.g. small molecule inhibitors), they are not applicable to molecular targets that lie within the membrane bilayer. The hydrophobic phospholipid bilayer imposes an impenetrable barrier to water-soluble polar therapeutic agents. We are probing EBV-LMP-1's Transmembrane Activation Domain with Synthetic Peptide Antagonist in attempt to find novel LMP-1 complexes.